Daniel Alencar Rodrigues (Daniel A Rodrigues)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 7

Top Venues

ChemMedChem

Pharmaceuticals (Basel, Switzerland)

Medicinal research reviews

Science translational medicine

Universidade Federal do Rio de Janeiro

Universidade Federal do Rio de Janeiro (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Universidade Federal do Rio de Janeiro Mar 01 2017 - Dec 31 2018

Brazil

Substitute Professor :: Organic Chemistry Departament

Education History

Universidade Federal do Rio de Janeiro Aug 01 2015 - Aug 09 2019

Brazil

PHD

Universidade Federal do Rio de Janeiro Mar 01 2013 - May 15 2015

Brazil

MSC

Universidade Federal de Goiás Mar 01 2008 - Jan 01 2013

Brazil

BSC :: College of Pharmacy

Publications

Thayssa Tavares da Silva Cunha, Rafaela Ribeiro Silva, Daniel Alencar Rodrigues, Pedro de Sena Murteira Pinheiro, Thales Kronenberger, Carlos Maurício R Sant'Anna, François Noël, Carlos Alberto Manssour Fraga
Design, Synthesis and Pharmacological Evaluation of Novel Conformationally Restricted N -arylpiperazine Derivatives Characterized as D 2 /D 3 Receptor Ligands, Candidates for the Treatment of Neurodegenerative Diseases. Biomolecules 12 (8) (2022)
Graeme P Sullivan, Lyndsey Flanagan, Daniel Alencar Rodrigues, Tríona Ní Chonghaile
The path to venetoclax resistance is paved with mutations, metabolism, and more. Science translational medicine 14 (674) (2022)
Fabiana Sélos Guerra, Daniel Alencar Rodrigues, Carlos Alberto Manssour Fraga, Patricia Dias Fernandes
Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer. Pharmaceuticals (Basel, Switzerland) 14 (5) (2021)
Daniel Alencar Rodrigues, Pedro de Sena Murteira Pinheiro, Carlos Alberto Manssour Fraga
Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol-3-kinase (PI3K): Current and Future Prospects. ChemMedChem 16 (3) (2020)
Daniel Alencar Rodrigues, Fabiana S Guerra, Fernanda S Sagrillo, Pedro de Sena M Pinheiro, Marina A Alves, Sreekanth Thota, Lorrane S Chaves, Carlos M R Sant'Anna, Patrícia D Fernandes, Carlos Alberto Manssour Fraga
Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors. ChemMedChem 15 (6) (2020)
Daniel Alencar Rodrigues, Pedro de Sena Murteira Pinheiro, Fernanda S Sagrillo, Maria Laura Bolognesi, Carlos Alberto Manssour Fraga
Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. Medicinal research reviews 40 (6) (2020)
Daniel Alencar Rodrigues, Fernanda S Sagrillo, Carlos Alberto Manssour Fraga
Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases. Pharmaceuticals (Basel, Switzerland) 12 (2) (2019)

Daniel Alencar Rodrigues.css-eqlu8i{font-size:small;padding-left:4px;} (Daniel A Rodrigues)

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel Alencar Rodrigues (Daniel A Rodrigues)